A Medical Device Daily

Ethicon Endo-Surgery (Cincinnati) reported Friday that the Anesthesiology and Respiratory Therapy Devices Advisory Committee of the FDA voted in favor of approval of the Sedasys System for use by physician/nurse teams to administer minimal-to-moderate propofol sedation during screening and diagnostic procedures for colorectal cancer (colonoscopy) and the upper gastrointestinal tract (EGD).

The Sedasys System is designed for physician/nurse teams to provide minimal-to-moderate sedation levels with propofol. The system automatically detects and responds to signs of over-sedation (oxygen desaturation and low respiratory rate/apnea) by stopping or reducing delivery of propofol, increasing oxygen delivery and automatically instructing patients to take a deep breath.

Ethicon said Propofol (also known as Diprivan) is considered by physicians to be a preferred sedative due to its rapid onset and quick, clear-headed recovery, which enables patients to promptly return to normal activities following a colonoscopy or EGD procedure.